Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $42.00

Дата публикации: 10-08-2026 05:48:47

Roivant Sciences (NASDAQ:ROIV – Free Report) had its price objective upped by Guggenheim from $36.00 to $42.00 in a report issued on Friday morning,Benzinga reports. They currently have a buy rating on the stock. Several other equities analysts have also recently weighed in on the company. Piper Sandler restated an “overweight” rating on shares of […]

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Genmab A/S (NASDAQ:GMAB) Price Target Raised to $42.00	0	9.76	10-08-2026
2	Royalty Pharma (NASDAQ:RPRX) Price Target Raised to $62.00	0	13.82	10-08-2026
3	BP (NYSE:BP) Price Target Raised to $43.00	0	12.22	10-08-2026
4	Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $146.00	0	14.22	10-08-2026
5	Guggenheim Cuts Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $23.00	0	9.15	10-08-2026
6	Avient (NYSE:AVNT) Price Target Raised to $50.00	0	13.46	10-08-2026
7	Avient (NYSE:AVNT) Price Target Raised to $48.00	0	14.17	10-08-2026
8	Five9 (NASDAQ:FIVN) Price Target Raised to $30.00	0	14.6	10-08-2026
9	Definium Therapeutics’ (DFTX) “Overweight” Rating Reiterated at Piper Sandler	0	8.75	10-08-2026
10	Applied Optoelectronics’ (AAOI) Buy Rating Reiterated at Rosenblatt Securities	0	10.32	10-08-2026

Классификация: Экономика. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 11.84. Источник: www.americanbankingnews.com.